Elevated Maternal Glycated Albumin is Associated with Large for Gestational Age Infants: Results from a Prospective Longitudinal Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Aims/hypothesis
Glycated albumin (GA) has been shown to be a moderate predictor of gestational diabetes mellitus (GDM), while evidence supporting its role in predicting adverse pregnancy outcomes remains limited. Here, we aimed to perform a comparative study of GA and haemoglobin A1c (HbA 1c ) for predicting GDM and large-for-gestational-age (LGA) infants in a prospective cohort.
Methods
We developed a rapid liquid chromatography-tandem mass spectrometry method for measuring site-specific albumin glycation. GA was quantified at two glycation sites, GA (KQT) and GA (KLV), as well as their sum, GA-total. GA was measured in stored serum samples collected at 11-14 and 23-31 gestational weeks from 465 participants in the single-centre observational cohort. HbA 1c was measured routinely at each visit. Linear mixed-effects models were used to compare GA between participants with and without GDM (n=100) or LGA (n=57). Logistic regression was used to estimate odds ratios (ORs) for GDM and LGA according to GA and HbA 1c .
Results
GA was lower in women who developed GDM during early pregnancy compared to non-GDM controls (GA-total; p =0.004), while in mid-late pregnancy, only GA (KQT) was lower in women with GDM ( p =0.036). In contrast, HbA 1c was higher in women with GDM at both timepoints compared to non-GDM controls ( p <0.001) and higher HbA 1c was associated with increased odds of GDM (OR=2.20, p <0.001; OR=2.30, p <0.001, respectively). GA was higher in the LGA group, in both early (GA-total; p =0.032) and mid-late pregnancy (GA-total; p =0.030) and associated with increased odds of LGA (GA-total; OR=1.59, p =0.009; GA-total; OR=1.46, p =0.019, respectively). HbA 1c was not associated with LGA at either timepoint.
Conclusions/interpretation
Higher GA in early and mid-late pregnancy were associated with an increased risk of LGA, whereas no significant association was observed for HbA 1c . GA may therefore provide risk assessment beyond HbA 1c for identifying pregnancies at risk of fetal overgrowth.
Research in Context
What is already known about this subject?
-
Glycated albumin (GA) has been proposed as a biomarker for GDM, LGA, and other adverse pregnancy outcomes.
-
HbA 1c is an established marker of chronic glycaemia outside pregnancy, but its role in the routine diagnosis and monitoring of GDM during pregnancy remains limited.
-
Both GA and HbA 1c are markers of glycaemic exposure; however, they capture different time frames and are influenced differently by the physiological changes of pregnancy.
What is the key question?
-
Are GA and HbA 1c measured during pregnancy associated with GDM and LGA?
What are the new findings?
-
HbA 1c and GA showed opposing associations with GDM development.
-
Higher GA in early and mid-late pregnancy were associated with an increased risk of LGA.
-
HbA 1c showed limited association with LGA.
How might this impact clinical practice in the foreseeable future?
-
GA and HbA 1c may serve as complementary biomarkers for assessing glycaemia and predicting pregnancy complications, with potential utility for improving risk stratification during pregnancy.